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mance status, complete resolution from extensive
cGVHD, and off all immunosuppressive drugs. Or,
for example, in a 65-year-old patient who has indeed
achieved a complete remission, I may be reluctant to
wean that patient off the last 5 mg of prednisone. In
many ways, perhaps we need a very good partial re-
sponse level for cGVHD, similar to what has been
suggested for aGHVD [3].
It would also have been helpful to know if the
differences in response were clouded by whether a pa-
tient was on a particular study drug compared with
those on prednisone alone. One obvious concern is
physician bias in calling responses for those patients
on an investigational drug [4]. The authors are to be
commended for calling our attention to this, as conclu-
sions from prior literature reporting high overall re-
sponse rates based on clinician judgment would not
be supported if the provisional algorithm had been ap-
plied to calculate response. These data again highlight
the importance of research rigor in cGVHD studies.
There are other factors that make cGVHD difficult
to study, not the least of which is that many of the pa-
tients are frequently far away from the medical center,
making both evaluation and certain therapies (ie,
photopheresis) difficult.
This analysis highlights the need to prospectively
define an overall response measure that incorporates
both patient-reported and objective measures, and ac-
curately reflects the outcome in patients. This is espe-
cially true when there is a mixed response where one
organ or site improves, while another shows new in-
volvement. What these data demonstrate is that we
very much need the validation of the NIH consensus
criteria, the studies of which are ongoing. Our field
would benefit considerably from something similar
to the Rodnan scores for systemic sclerosis. I would
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Despite some concerns regarding this instrument, it
has been pivotal in allowing for a uniform language,
measuring the disease, and facilitating progress in the
choice of therapies.
In summary, we are reminded of the curmudgeon
H.L. Mencken who stated, ‘‘For every complex prob-
lem, there is a solution that is simple, neat, and
wrong.’’ The authors of this article have provided
a very important framework for clinical trials going
forward.We must measure with greater rigor and pre-
cision if we want to help our patients.We as a commu-
nity must also show our commitment to our patients
by participating in large, well-designed studies such
as those led by the Clinical Trials Network. We need
clear definitions that can be understood by all, studies
with sufficient patients that allow for robust statistics,
and a measure of thought regarding the biology of this
disease process.ACKNOWLEDGMENTS
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Steven M. DevineAfter years of development culminating in Food and
Drug Administration approval in the wake of 2 success-
ful phase 3 studies, there is little doubt as to the biolog-
ical and clinical activity of the first in class CXCR4
antagonist plerixafor [1,2]. The benefit of addingplerixafor to granulocyte-colony stimulating factor
(G-CSF) for optimal mobilization of a sufficient
CD341 cell product was demonstrated convincingly
in phase 3 studies conducted separately in patients
with multiple myeloma (MM) and non-HodgkinStarling Loving Hall, 320 W 10th Avenue, Columbus,
OH 43210 (e-mail: Steven.Devine@osumc.edu).
Received August 4, 2012; accepted August 7, 2012
 2012 American Society for Blood and Marrow Transplantation
1083-8791/$36.00
http://dx.doi.org/10.1016/j.bbmt.2012.08.001
Biol Blood Marrow Transplant 18:1467-1470, 2012 1469The Bottom Linelymphoma [1,2]. If not for its extremely high cost,
plerixafor would likely enjoy widespread use for stem/
progenitor cell mobilization because it is effective and
relatively safe. However, it is very costly, and this fact
has forced most bone marrow transplant programs to
consider how best to use it. At the 2 extremes,
programs could use it in all of their planned
autologous transplantation recipients in order to
ensure an adequate CD341 cell mobilization, or
alternatively its use could be reserved only after
a patient fails a first attempt at mobilization. Neither
of these strategies seems to make a lot of sense and,
thus, the majority of programs have been left to
decide how best to balance the pros of plerixafor
(efficacy, predictability, and relative safety) with its
cons (cost and relative inconvenience due to timing of
administration). The recent deluge of manuscripts
published following Food and Drug Administration
approval of plerixafor focusing on its potential clinical
benefits or cost effectiveness relative to chemotherapy
based mobilization have facilitated the development of
individual strategies, but in the end there is still
some guesswork involved [3-8]. A publication by
Nademanee et al. [9] in this issue of Blood and Bone
Marrow Transplantation should, hopefully, take some
of that guesswork out of the equation. This post hoc
analysis focuses on the capacity of plerixafor to salvage
patients who seem to be mobilizing poorly after
G-CSF alone. Results of peripheral blood CD341
cell analysis taken on day 4 of G-CSF administration
in patients with MM enrolled on the phase 3 trial
were available in.80% of the enrollees. In general, pa-
tients with a CD341 cell count of\10/uL on day 4 of
G-CSF alone are destined to do poorly and are at high
risk of mobilization failure (ie, fail to collect at least
2  106 CD341 cells/kg). It is in these patients that
plerixafor may bemost useful, as patients in this analysis
with CD34 counts \10 achieved a median 9.6-fold
increase in CD341 cell count from day 4 to day 5 com-
pared to only 2.0-fold in the placebo-control group.
Ultimately .90% of these patients mobilized success-
fully compared to only 70% in the placebo group. In
all groups analyzed based on day 4 CD341 cell count,
the addition of plerixafor toG-CSF resulted in amedian
8-fold increase on day 5 compared to about 2-fold with
G-CSF alone. Notwithstanding, it does not seem that
all patients with MM require plerixafor to mobilize
with G-CSF alone because more than half will have
a day 4 count$20 and more than 95% of these patients
will collect at least 2 106 CD341 cells/kg in 2 apher-
esis sessions. It all depends on the bone marrow trans-
plant center goals regarding minimum and so-called
‘‘optimum’’ mobilization.
This does beg the question of the term ‘‘optimum
mobilization.’’ Almost everyone will accept that robust
CD341 cell mobilization is a good thing, but to what
extent should we go to pursue the so-called optimumdose of 5-6  106 CD341 cells/kg? There is no strong
evidence that CD341 cell doses above 2 106 CD341
cells/kg are associated with any substantial clinical ben-
efits. There are no reliable data suggesting a survival ad-
vantage to higherCD341 cell doses and any advantages
in terms of either early hospital discharge or less use of
platelet transfusions are slight at best [1,2]. In fact
a study by Stiff et al. [10] could not demonstrate any
early advantage associated with the infusion CD341
doses above 2  106 CD341 cells/kg in the non-
Hodgkin lymphoma phase 3 trial evaluating plerixafor.
That study did suggest a greater proportion of patients
had durable platelet engraftment after higher CD341
cell doses, but to what extent this translated into any
clinical benefit was unclear. The most convincing theo-
retical and as yet unproven argument to bemade for ad-
ministering CD341 cell doses higher than 2  106
CD341 cells/kg is that it may facilitate the long-term
administration of maintenance therapy postautograft.
Because posttransplantation administration of mainte-
nance lenalidomide was recently shown to improve
survival in patients withMM, this theoretical advantage
may provide a good rationale, although it is unlikely to
be substantiated in any clinical trial setting [11]. The
Cleveland Clinic group reported on so-called ‘‘super
mobilizers,’’ patients who receive very high CD341
cell doses after high-dose chemotherapy, and this was
associated with a survival advantage [12]. However,
these data are uncontrolled and more than likely the
capacity to mobilize a very high CD341 cell product
represents a surrogate for a less heavily pretreated, bet-
ter risk patient.
Finally, there is the ongoing debate as to whether
patients should be mobilized after recovery from mye-
losuppressive chemotherapy vs after G-CSF with or
without plerixafor. Here the argument is that G-CSF
plus plerixafor may be cost effective and safer than
chemotherapy based mobilization, but without pro-
spective comparative trials, this debate remains largely
unresolved and programs typically continue to do what
they have done historically [7]. In patients with MM,
there is the issue of whether a sufficient CD341 cell
dose to support 2 transplantations should be collected
upfront in all patients. Although second transplanta-
tions in MM are prevalent in Europe (although they
are on the decline), the true value of performing a sec-
ond transplantation in the era of maintenance lenali-
domide remains the subject of ongoing study and,
currently, few patients who have CD341 cells mobi-
lized and collected for 2 autografts will ever use those
cells, particularly as novel drugs are being developed.
At the end of the day, centers will be left to decide
on their own which is the most appropriate strategy.
Costa et al. [4,13] have recently published what seems
to be a rational strategy based on knowledge of the
center’s target CD341 cell dose, its mean apheresis
collection efficiency, and overall costs to arrive at an
1470 Biol Blood Marrow Transplant 18:1467-1470, 2012S. M. Devinealgorithm that uses analysis of the day 4 CD341 cell
level to decide whether plerixafor should be added to
G-CSF. The data presented in this issue of Blood and
Bone Marrow Transplantation by Nademanee et al. [9]
seem to support similar strategies.ACKNOWLEDGMENTS
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